Australia's Neuren Pharmaceuticals rises on positive results from Phase 2 drug trials

Neuren Pharmaceuticals

23/12/2022 24:49

** Shares of Neuren Pharmaceuticals Ltd  NEU.AX  riseas much
as 3.7% to A$8.09, their highest since Dec 1
    ** Biopharmaceutical co says first patients complete Phase 2
drug trials for genetic disorders, Angelman syndrome and
Phelan-McDermid syndrome
    ** Says drug trials show good safety and tolerability in
patients  
    ** Co also submits an Investigational New Drug application
for a drug used to treat genetic disorder, Prader-Willi syndrome
    ** Shares of co are up 106.9% YTD as of last close 
 (Reporting by John Biju in Bengaluru)
 ((John.Biju@thomsonreuters.com;))